With persistent issues of corruption and counterfeiting, China has implemented various policies to address its troubled pharmaceutical industry. From the antibiotic Xinfu scare, which led to at least 10 deaths to a bribery investigation of the former head of the State Food... Read More
INTRODUCTION China is the fastest growing economy in the world today. In 2004, GDP in China grew by 9.0%, while in 2005 it grew by 9.8%. Analysts predict that China’s economy will continue to grow at 8% to 9% per annum through... Read More
The Singapore Parliament is conducting a preliminary review on new legislation to regulate all health products and active ingredients. The Health Products Bill was first presented to the Parliament on January 22, 2007. It seeks to regulate the manufacture, import, supply, presentation,... Read More
China's economy is growing rapidly, and so are standards of production. As its manufacturers continue to develop more sophisticated processes and products, quality standards are increasing dramatically. Medical devices are no exception. China's medical device market has grown to $6 billion, the... Read More
The World Health Organization (WHO) and various international partners came together in Germany November 2006 to develop a task force focused on preventing the global spread of counterfeit medicines. The International Medical Products Anti-Counterfeiting Taskforce, or IMPACT would cover legal, technological, communications... Read More
While orphan drug laws in Asia may provide benefits for companies registering new drugs, such as marketing exclusivity, an expedited registration process, and a reduction in the number of clinical trials required, each registration process is unique and can pose a variety... Read More
The Asian economy has experienced tremendous GDP growth over the past decade, and is expected to continue at a healthy pace for the next several years. In particular, the medical device market has been growing quite rapidly. More and more companies are... Read More
The Indian government has issued an order to change the Drugs Prices Control Order (1995) that will change the new maximum retail price (MRP) for drugs. Pharmaceutical companies will now have to comply with the new MRP system as of July 2006—all... Read More
The U.S. International Trade Commission will be conducting a fact-finding investigation into the competitive conditions in Japan and other foreign markets for medical devices and equipment. The investigation will focus on comparing the regulatory environment in Japan with those of other countries... Read More
In April 2006, the Chinese government opened a new Administrative Service Center to handle license applications for new medical devices and drugs in China more efficiently. This center, which is part of the State Food and Drug Administration (SFDA), will undertake administrative... Read More